At the moment (closing price from March 17, 2017) -
AGN: 237.38
VRX: 11.03 (but on July 31, 2015, it was at 257.53)
Mr. Ackman's $4 billion loss in Valeant more than wiped out the $2.2 billion he made in 2014 on Allergan. Mr. Ackman had never invested in the pharmaceutical industry when he put over $3 billion into Allergan.
In an email to The New York Times, Pershing Square said, "Valeant is an anomaly in an outstanding record over nearly 14 years."
But while his funds notched an exceptional 40 percent gain in 2014 — much of it attributable to the Allergan trade that has drawn the lawsuit — Mr. Ackman’s funds lost 13.5 percent last year and 20.5 percent in 2015. Through March 15, Pershing Square is flat. Other hedge funds have turned in poor performances as well in recent years. And it is not clear whether or to what extent Mr. Ackman’s investors have reacted to his firm’s losses by fleeing. Pershing Square declined to disclose redemption figures.
Timeline:
And from the other day:
Ackman's Valeant Holdings Lost Pershing $7.7 Million a Day
Look at the acquisition spree that Allergan itself was on, over the past few years! See how many times "Acq" appears on the chart! No wonder he thought, in May 2015, that Valeant could be a "very early-stage Berkshire" -
Submitted March 20, 2017 at 06:55AM by tellman1257 http://ift.tt/2ndyfXT
